Hydroxyethylstärke (HES): Neubewertung durch das Pharmacovigilance Risk Assessment Committee (PRAC)

Zusammenfassung

At the request of the German Federal Institute for Drugs and Medical Devices (BfArM), the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review procedure regarding the basic evaluation of the benefit-risk balance of solutions for infusion containing hydroxyethyl starch (HES). Here we present an overview of facts to provide emergency physicians objective information.